Last reviewed · How we verify
T89 capsule — Competitive Intelligence Brief
phase 3
Herbal/Traditional medicine derivative; cardiac metabolic agent
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
T89 capsule (T89 capsule) — Tasly Pharmaceuticals, Inc.. T89 is a traditional Chinese medicine-derived compound that improves myocardial energy metabolism and enhances cardiac function through multiple pathways.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| T89 capsule TARGET | T89 capsule | Tasly Pharmaceuticals, Inc. | phase 3 | Herbal/Traditional medicine derivative; cardiac metabolic agent |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Herbal/Traditional medicine derivative; cardiac metabolic agent class)
- Tasly Pharmaceuticals, Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- T89 capsule CI watch — RSS
- T89 capsule CI watch — Atom
- T89 capsule CI watch — JSON
- T89 capsule alone — RSS
- Whole Herbal/Traditional medicine derivative; cardiac metabolic agent class — RSS
Cite this brief
Drug Landscape (2026). T89 capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/t89-capsule. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab